Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Differences Hinder Japan's Participation in Int'l Joint Clinical Trials
September 19, 2005
- AstraZeneca Standardizes Marketing Methods Worldwide
September 19, 2005
- Dr Iwasaki of EFPIA Japan Proposes Multiple-consultation System
September 19, 2005
- GSK's New Augmentin Dosage Form, Bayer's Moxifloxacin Recommended for Approval
September 12, 2005
- Pharmacists Should Be Responsible for Supplying GE Drug Info.: Prof. Masuhara
September 12, 2005
- COMMENTARY 4 articles
September 12, 2005
- Mr Matsubara of JPA Calls For Restriction on Long-term Prescriptions
September 12, 2005
- METI Will Not Ask for Hike in Tax Exemption Ceiling for R&D
September 12, 2005
- Korosho Presents Petition Asking for Preferential Taxation
September 12, 2005
- MEDICAL DEVICE NEWS IN BRIEF
September 12, 2005
- METI to Support Genome-based Drug Discovery: FY2006 Budget
September 12, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 12, 2005
- Korosho Asks for 3.5% Increase in General Accounts Budget
September 12, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
September 12, 2005
- NHI Prices Recommended for Approval for 6 Products
September 12, 2005
- Medical Expenditure for Clinics Rose 2.5% in FY2004: HIB
September 12, 2005
- AstraZeneca Aims for 4.2% Share of Domestic Market by 2010
September 12, 2005
- R&D NEWS IN BRIEF
September 12, 2005
- SELF-MEDICATION NEWS IN BRIEF
September 12, 2005
- Statistics
September 12, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…